Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Osteoporosis, Postmenopausal 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × tibolone × Clear all
NCT00725374 2024-08-15

STEM

Organon and Co

Phase 3 Completed
102 enrolled
Breast

Breast Neoplasms

NCT00408863 2022-02-04

Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)

Organon and Co

Phase 3 Completed
3,148 enrolled
Breast

Breast Neoplasms

NCT00165204 2007-12-21

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled
Breast

Breast Neoplasms, Osteoporosis, Postmenopausal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡